| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.4 | 0.7 |
| Profit before tax | -4.6 | -4.2 |
| Net income | -4.6 | -4.2 |
| EPS (diluted, $ a share) | $-0.53 | $-2.05 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -44.5% |
|---|
10-Q filed with the SEC, NASDAQ: FEMY. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Femasys Inc: key numbers
- Share price
- $1.12Close, Nov 17
- Market cap
- $9.7M
- Shares outstanding
- 8.66MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Femasys Inc
All →Femasys Financial Results
Femasys reported financial results for the third quarter of 2026, highlighting a slight increase in U.S. sales to $0.35 million despite overall sales declining due to international distributor order timing. The company completed a $30 million private placement in August to fund the build-out of its U.S. commercial team and support the FemBloc pivotal trial.
- Term
- Q3 2026
“We maintained a lean team and tightly managed resources as we prioritized financing from long-term institutional investors. Closing the $30 million in financing in mid-August 2026 represents an important turning point for Femasys.”
Kathy Lee-Sepsick, Founder and Chief Executive Officer
“These results and commercial recruitment progress give us strong confidence that deploying our team in target U.S. territories will broaden adoption and drive revenue growth.”
Kathy Lee-Sepsick, Founder and Chief Executive Officer
Femasys Leadership Change
Femasys Inc. announced the appointment of John Moorhead to its Board of Directors as a designee of Nantahala Capital Management, LLC, effective October 30, 2026. Simultaneously, Dr. Kenneth D. Eichenbaum resigned from the Board following the termination of Pointillist Partners LLC's board nomination rights. Mr. Moorhead, a former Chief Marketing Officer at Unilever's Seventh Generation, will serve as a Class II director and join the Audit and Compensation Committees.
- Counterparty
- Nantahala Capital Management, LLC